Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies

Odronextamab is a fully‐human IgG4‐based CD20xCD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering T‐cell‐mediated cytotoxicity independent of T‐cell‐receptor recognition. Adequate safety, tolerability, and encouraging durable complete responses have been observed in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Min, Olson, Kara, Kirshner, Jessica R., Khaksar Toroghi, Masood, Yan, Hong, Haber, Lauric, Meagher, Craig, Flink, Dina M., Ambati, Srikanth R., Davis, John D., DiCioccio, A. Thomas, Smith, Eric J., Retter, Marc W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010254/
https://www.ncbi.nlm.nih.gov/pubmed/34997701
http://dx.doi.org/10.1111/cts.13212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010254/
https://www.ncbi.nlm.nih.gov/pubmed/34997701
http://dx.doi.org/10.1111/cts.13212

Ejemplares similares